NAMS 241220 35.00C (NAMS241220C35000) Stock Options, News & Quotes

0.20
-0.55-73.33%

15min DelayClose Nov 29 10:46 ET

0.20High0.20Low

SymbolStock Name

Latest PriceChg% ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D % Chg10D % Chg20D % Chg60D % Chg120D % Chg250D % Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry

WatchlistPaper Trade

Comments

Jaguar8

Nov 20 08:16

NEWS

$NewAmsterdam Pharma (NAMS.US)$
NewAmsterdam Pharma Announces Positive Topline Data from Pivotal Phase 3 TANDEM Clinical Trial Evaluating the Fixed-Dose Combination of Obicetrapib 10 mg and Ezetimibe 10 mg in Patients with ASCVD or ASCVD Risk Factors and/or HeFH
-- Achieved all co-primary endpoints of LS mean reduction in LDL-C on top of maximally tolerated lipid-modifying therapies versus each of placebo, ezetimibe 10 mg, and obicetrapib 10 mg monotherapy at day 84 with statistical significa...

SkinnyChick

Nov 20 06:18

$NewAmsterdam Pharma (NAMS.US)$ on watch

北美深蓝

Jul 30 03:54

⛔本次下跌合理吗？

$NewAmsterdam Pharma (NAMS.US)$ ⭕NewAmsterdam Pharma（NAMS）周一表示，对于家族性高胆固醇血症杂合子患者潜在降低胆固醇的药物obicetrapib的3期临床研究已达到主要终点，但是，股价却在消息发布后跌超8%，为此，找到相关本次临床相关信息以便进一步评估其下跌：
🔺obicetrapib是用于治疗低密度脂蛋白胆固醇（“LDL-C”）升高且有心血管疾病（“CVD”）风险的患者，这些患者现有疗法效果不够好或耐受性不佳
🔺本次临床试验的对象及其入选条件
Study Overview
Brief Summary
This study will be a placebo-controlled, double-blind, randomized, phase 3 study to Evaluate the Efficacy, Safety, and Tolerability of Obicetrapib in Participants with a History of Heterozygous Familial Hyper...

Meltyy

May 16 01:19

🔔 RA Capital Q1 ‘24* Holdings Released... 🐳

» Holdings: 75
» Holdings in Top 20: 70.21%
» Qtr over Qtr Change**: +21.81%
Top Holdings:
$Ascendis Pharma A/S (ASND.US)$
$Vaxcyte (PCVX.US)$
$Legend Biotech (LEGN.US)$
$Janux Therapeutics (JANX.US)$
$Aerovate (AVTE.US)$
$Rhythm Pharmaceuticals (RYTM.US)$
$Evolent Health (EVH.US)$
$NewAmsterdam Pharma (NAMS.US)$
$RxSight (RXST.US)$
$TYRA BIOSCIENCES, INC. (TYRA.US)$
$Edgewise Therapeutics (EWTX.US)$
$4D Molecular Therapeutics (FDMT.US)$
$Biogen (BIIB.US)$
$PepGen (PEPG.US)$
...

Moomoo AI

Mar 3 06:36

Analysts have upgraded revenue forecasts for NewAmsterdam Pharma next year, despite slower expected growth than the industry. They also increased the price target, indicating an improved intrinsic business value.

NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS) Reported Earnings Last Week And Analysts Are Already Upgrading Their Estimates